The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
Access to genomic testing, not therapy cost, is the biggest challenge
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
Subscribe To Our Newsletter & Stay Updated
